Cargando…
Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
The first-line therapy in advanced kidney cancer has changed in recent years due to the introduction of combinations of tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor receptors (VEGFR) and immune checkpoint inhibitors (ICIs). Although immune-related adverse events are well-k...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755843/ https://www.ncbi.nlm.nih.gov/pubmed/36530979 http://dx.doi.org/10.3389/fonc.2022.1048526 |